Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1


  1. Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.

    Article  CAS  Google Scholar 

  2. Ngo V, Ryan M, Schmitz R, Jhavar S, Xiao W, Lim K et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115–119.

    Article  CAS  Google Scholar 

  3. Jiménez C, Sebastián M, Chillón M, Giraldo P, Mariano J, Escalante F et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia 2013; 27: 1722–1728.

    Article  Google Scholar 

  4. Krol ADG, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM . Primary extranodal non-Hodgkin’s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 2003; 14: 131–139.

    Article  CAS  Google Scholar 

  5. Choi J-W, Kim Y, Lee J-H, Kim Y-S . MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Hum Pathol 2013; 44: 1375–1381.

    Article  CAS  Google Scholar 

  6. Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012; 18: 5203–5211.

    Article  CAS  Google Scholar 

  7. Kraan W, Horlings HM, van Keimpema M, Schilder-Tol EJM, Oud MECM, Scheepstra C et al. High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 2013; 3: e139.

    Article  CAS  Google Scholar 

  8. Bohers E, Mareschal S, Bouzelfen A, Marchand V, Ruminy P, Maingonnat C et al. Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2014; 53: 144–153.

    Article  CAS  Google Scholar 

  9. Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJM, MECM Oud, Noorduyn LA et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia 2013; 28: 719–720.

    Article  Google Scholar 

  10. Pham-Ledard A, Cappellen D, Martinez F, Vergier B, Beylot-Barry M, Merlio JP . MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol 2012; 132: 2118–2120.

    Article  CAS  Google Scholar 

  11. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282.

    Article  CAS  Google Scholar 

  12. Young RM, Staudt LM . Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229–243.

    Article  CAS  Google Scholar 

  13. Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ et al. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 2013; 122: 1222–1232.

    Article  CAS  Google Scholar 

  14. Treon S, Tripsas C, Yang G, Cao Y, Xu L, Hunter Z et al. A prospective, multicentre, phase II study of the Bruton’s tyrosine kinase inhibitor ibrutinib in patients with relapsed and refractory Waldenstrom’s macroglobulinemia. Hematol Oncol 2013; 31 (Suppl 1): 119 (abstract 067).

    Google Scholar 

  15. Wilson WH, Gerecitano JF, Goy A, de Vos S, Kenkre VP, Barr PM et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood (ASH Annu Meet Abstr) 2012; 120, abstract 686.

Download references


This work was supported by RD09/0076/0036, PT13/0010/0005, 2014 SGR 567 and the ‘Xarxa de Bancs de tumors’ sponsored by Pla Director d'Oncologia de Catalunya (XBTC). CF-R received a fellowship from the Ministry of Economy and Competitiveness of Spain (PFIS grant FI11/00353).

Author information

Authors and Affiliations


Corresponding author

Correspondence to A Salar.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fernández-Rodríguez, C., Bellosillo, B., García-García, M. et al. MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma. Leukemia 28, 2104–2106 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links